Get Our Latest Analysis on NBIX Neurocrine Biosciences Price Performance NASDAQ NBIX opened at $148.73 on Friday. The company has a market capitalization of $15.06 billion, a price-to-earnings ...

Neurocrine Biosciences Inc. has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and Device. In this role, Ratz will lead the transformation of Neurocrine’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you’re on the fence about investing in AbbVie Inc., Neurocrine Biosciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development ...

$830,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia ...